Beclin-1、苯并咪唑出芽抑制解除同源物蛋白1在非小细胞肺癌中的表达及对预后的影响

Expression of Beclin-1 and budding uninhibited by benzimidazoles 1 in nonsmall cell lung cancer and their effect on prognosis

目的探讨Beclin-1、苯并咪唑出芽抑制解除同源物蛋白1(BUB1)在非小细胞肺癌(NSCLC)中的表达及对预后的影响。方法收集109例NSCLC患者的临床资料,并选取其肿瘤组织及癌旁正常组织。比较不同组织中Beclin-1、BUB1阳性表达情况,分析二者与NSCLC患者临床特征的关系;随访2年,比较不同预后情况患者的Beclin-1、BUB1表达情况。结果肿瘤组织中Beclin-1阳性表达率明显低于癌旁正常组织,BUB1阳性表达率明显高于癌旁正常组织,差异均有统计学意义(P﹤0.01)。不同分化程度、TNM分期及淋巴结转移情况NSCLC患者的NSCLC组织中Beclin-1及BUB1阳性表达率比较,差异均有统计学意义(P﹤0.01)。死亡患者Beclin-1阳性表达率低于生存患者,BUB1阳性表达率高于生存患者,差异均有统计学意义(P﹤0.05)。结论Beclin-1、BUB1参与NSCLC的发生、发展过程,且Beclin-1阴性表达、BUB1阳性表达会增加NSCLC患者预后死亡的风险。

Objective To investigate the expression of Beclin-1 and budding uninhibited by benzimidazoles 1(BUB1)in non-small cell lung cancer(NSCLC)and their effect on prognosis.Method The clinical data of 109 NSCLC patients were collected,and their tumor tissues and adjacent normal tissues were selected.The positive expression of Beclin-1 and BUB1 in different tissues and their relationship with the clinical characteristics of NSCLC patients were analyzed.The follow-up lasted for 2 years,and the expression of Beclin-1 and BUB1 in patients with different prognoses were also compared.Result The positive expression rate of Beclin-1 in tumor tissues was significantly lower than that in adjacent normal tissues,BUB1 in tumor tissues was significantly higher than that in adjacent normal tissues,the differences were statistically significant(P<0.01).There were significant differences in the positive expression rates of Beclin-1and BUB1 in NSCLC tissues of NSCLC patients with different differentiation degrees,TNM stages,and lymph node metastasis(P<0.01).The positive expression rate of Beclin-1 in the dead patients was lower than that in the patients alive,and the positive expression rate of BUB1 was higher than in those who were alive,and the differences were statistically significant(P<0.05).Conclusion Beclin-1 and BUB1 are involved in the initial and development of NSCLC,and the negative expression of Beclin-1 and the positive expression of BUB1 will increase the risk of death in patients with NSCLC.